Categories: Wire Stories

China CBD and Cannabis Market Regulatory Framework Report 2021: Processing, Cultivation, Extracts, Finished Products, Imports and Exports – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “CBD Regulatory Report: China” report has been added to ResearchAndMarkets.com’s offering.

This report provides a detailed look at the current regulatory framework in place for CBD and cannabis in mainland China, as well as Yunnan and Heilongjiang provinces, covering all areas from processing and cultivation, to extracts, finished products and import and export.

China has a long history of growing hemp for fibre, traditional therapeutic use and for using hemp seeds in food. In particular, cultivation to use hemp seed in traditional food – extracting oil and making herbal tea for example – is common in several provinces. Cannabis and cannabis extracts are controlled substances under national legislation in China, and two provinces – Yunnan and Heilongjiang – have established hemp and CBD regulation.

Key Topics Covered:

1 Executive summary

2 Outlook

3 Hemp

4 Extracts as finished product

5 Finished products

6 Import and export requirements

7 Minor cannabinoids

8 Medical cannabis

9 Recreational cannabis

10 Relevant laws

11 Relevant bodies

For more information about this report visit https://www.researchandmarkets.com/r/7lbd6i

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Alex

Recent Posts

Power Integrations Launches Single-Board Plug-and-Play Gate Drivers for 1.2 kV to 2.3 kV “New Dual” IGBT Modules

NTC temperature readout improves accuracy, increasing reliability and module utilization by up to 30 percent…

16 mins ago

YY Group Expands into Australian Hospitality and Hotel Industry

SINGAPORE, May 21, 2024 (GLOBE NEWSWIRE) -- YY Group Holding Limited (NASDAQ: YYGH) (“YY Group”,…

17 mins ago

Qurient Therapeutics Enters CRADA with the National Cancer Institute to Collaborate on a Phase 1/2 Clinical Study of Q901 in Combination with TROP2-ADC

SEONGNAM-SI, South Korea--(BUSINESS WIRE)--#Qurient--Qurient Co. Ltd. (KRX: 115180), a clinical-stage biotech company based in Korea,…

18 mins ago

SurveyMonkey Announces the Return of Curiosity Con

The free virtual summit will feature a keynote by Magic Johnson and industry-specific sessions for…

19 mins ago

Qraft Technologies’ Flagship ETFs AMOM and QRFT Celebrate 5th Anniversary with Powerful Performance Milestones

The premier AI-managed ETFs ring in their fifth birthday with a proven track record of…

20 mins ago